Immunology and Biotherapies
12.9K views | +5 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability - Online First - Springer

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability - Online First - Springer | Immunology and Biotherapies | Scoop.it
Abstract

The convergence of advanced understanding of biology with chemistry has led to a resurgence in the development of antibody-drug conjugates (ADCs), especially with two recent product approvals. Design and development of ADCs requires the synergistic combination of the monoclonal antibody, the linker and the payload. Advances in antibody science has enabled identification and generation of high affinity, highly selective, humanized or human antibodies for a given target. Novel linker technologies have been synthesized and highly potent cytotoxic drug payloads have been created. As the first generation of ADCs utilizing lysine and cysteine chemistries moves through the clinic and into commercialization, second generation ADCs involving site specific conjugation technologies are being evaluated and tested. The latter aim to be better characterized and controlled, with wider therapeutic indices as well as improved pharmacokinetic-pharmacodynamic (PK-PD) profiles. ADCs offer some interesting physicochemical properties, due to conjugation itself, and to the (often) hydrophobic payloads that must be considered during their CMC development. New analytical methodologies are required for the ADCs, supplementing those used for the antibody itself. Regulatory filings will be a combination of small molecule and biologics. The regulators have put forth some broad principles but this landscape is still evolving.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 24, 2015 1:57 AM
Pharmaceutical ResearchMay 2015Date: 19 May 2015Antibody-Drug Conjugates: Design, Formulation and Physicochemical StabilitySatish K. Singh, Donna L. Luisi, Roger H. Pak
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Best Selling Monoclonal Antibodies 2013

Best Selling Monoclonal Antibodies 2013 | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
Gilbert C FAURE's insight:

impressive for immunologists so far away from so big amounts of money

more...
Krishan Maggon 's curator insight, January 6, 2014 8:38 AM

Abstract

 

A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table.  Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014).  Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.

 

Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Antibody–drug conjugates: targeted weapons against cancer | ANTI

Antibody–drug conjugates: targeted weapons against cancer | ANTI | Immunology and Biotherapies | Scoop.it
Antibody–drug conjugates: targeted weapons against cancer Luisa Iamele, Luca Vecchia, Claudia ScottiDepartment of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, PV, Italy All authors contributed equally...

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, February 11, 2015 3:52 AM
REVIEW  Antibody Technology JournalAntibody–drug conjugates: targeted weapons against cancer         AbstractFulltextMetricsGet Permission

Authors Iamele L, Vecchia L, Scotti C

Published Date January 2015 Volume 2015:5 Pages 1—13

DOI http://dx.doi.org/10.2147/ANTI.S52914

Received 11 September 2014, Accepted 22 November 2014, Published 9 January 2015

Approved for publication by Dr Shixia Wang

Luisa Iamele, Luca Vecchia, Claudia Scotti

Department of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, PV, Italy

GLG Pharma's curator insight, February 17, 2015 7:44 AM

Good review of how antibody conjugates work.